Focus Partners Advisor Solutions LLC Grows Stock Position in Medpace Holdings, Inc. $MEDP

Focus Partners Advisor Solutions LLC increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 229.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,487 shares of the company’s stock after acquiring an additional 3,126 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Medpace were worth $2,307,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of MEDP. Fisher Asset Management LLC increased its stake in Medpace by 9.9% in the 3rd quarter. Fisher Asset Management LLC now owns 137,746 shares of the company’s stock worth $70,824,000 after purchasing an additional 12,399 shares during the period. Journey Strategic Wealth LLC grew its holdings in shares of Medpace by 21.8% in the third quarter. Journey Strategic Wealth LLC now owns 884 shares of the company’s stock worth $455,000 after purchasing an additional 158 shares during the last quarter. Aprio Wealth Management LLC bought a new position in shares of Medpace in the third quarter worth approximately $317,000. American Century Companies Inc. increased its stake in shares of Medpace by 131.0% in the third quarter. American Century Companies Inc. now owns 29,370 shares of the company’s stock worth $15,101,000 after buying an additional 16,653 shares during the period. Finally, Handelsbanken Fonder AB raised its holdings in Medpace by 16.7% during the 3rd quarter. Handelsbanken Fonder AB now owns 7,700 shares of the company’s stock valued at $3,959,000 after buying an additional 1,100 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Truist Financial cut their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Leerink Partners dropped their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a report on Tuesday, February 10th. Finally, Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Trading Up 0.1%

Shares of MEDP opened at $465.86 on Thursday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The firm’s 50-day moving average price is $537.93 and its 200-day moving average price is $538.85. The firm has a market capitalization of $13.22 billion, a price-to-earnings ratio of 30.45, a PEG ratio of 2.23 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the business posted $3.67 earnings per share. Medpace’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.